癌细胞的新陈代谢振荡和甘油溶解表型
Takashi Amemiya1, Kenichi Shibata1, Tomohiko Yamaguchi2
1Graduate School of Environment and Information Sciences, Yokohama National University (YNU), 79-7 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan.
International journal of molecular sciences
|August 12, 2023
概括
癌细胞在糖解中表现出代谢振荡. 这些振荡的更高频率,通过尼古丁胺氨酸二核酸 (NADH) 自流光监测,与癌细胞恶性病变和糖解酶活性增加相关.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
背景情况:
- 癌细胞表现出多样化的代谢表型,其中一个与恶性瘤相关的突出的糖溶性表型.
- 了解癌细胞代谢对于开发诊断和治疗策略至关重要.
研究的目的:
- 为了研究癌细胞中的糖溶性振荡.
- 为了确定这些振荡是否可以作为癌细胞恶性瘤的指标.
主要方法:
- 监测HeLa宫癌和DU145前列腺癌细胞中的代谢振荡,使用尼古丁胺胺氨酸二核酸 (NADH) 的细胞自光.
- 分析球形和单层细胞形态的振荡.
- 开发一种数学模型,以定量评估糖解酶活性和振荡频率.
主要成果:
- 在癌细胞代谢产物中观察到明显的糖分溶解振荡.
- 证明更高的振荡频率与增加的糖溶性活性和恶性瘤相关.
- 通过数学模型验证了实验结果,将更高的频率归因于高糖解酶活性.
结论:
- 糖解质振荡是癌细胞中可测量的现象.
- 这些振荡的频率可以作为评估癌细胞恶性病变的潜在医学指标.
- 这一发现为癌症研究中的新型诊断方法开辟了道路.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Other Glycolytic Pathways
47
The pentose phosphate pathway (PPP) operates in parallel with glycolysis, facilitating the metabolism of both pentoses and glucose. This pathway consists of two distinct phases: the oxidative and non-oxidative phases. While it does not directly generate ATP, the intermediates formed during the process can integrate into glycolysis, contributing to cellular energy metabolism when required.Oxidative Phase: NADPH ProductionThe oxidative phase of the pentose phosphate pathway is primarily...
47
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Cancers Originate from Somatic Mutations in a Single Cell
12.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.0K


